Egalet Corp. (NASDAQ:EGLT) traded up 2% during trading on Tuesday . The company traded as high as $7.38 and last traded at $7.21, with a volume of 381,147 shares changing hands. The stock had previously closed at $7.07.

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald set a $21.00 price objective on shares of Egalet Corp. and gave the company a “buy” rating in a research report on Saturday, August 6th. Zacks Investment Research downgraded shares of Egalet Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Finally, Gabelli assumed coverage on shares of Egalet Corp. in a research report on Tuesday, September 13th. They issued a “buy” rating and a $9.50 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Egalet Corp. presently has a consensus rating of “Hold” and a consensus price target of $14.40.

The company’s market capitalization is $176.96 million. The stock’s 50-day moving average price is $7.63 and its 200 day moving average price is $6.49.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/egalet-corp-eglt-trading-2-higher.html

Egalet Corp. (NASDAQ:EGLT) last announced its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.15. Egalet Corp. had a negative net margin of 244.57% and a negative return on equity of 86.03%. The business had revenue of $3.45 million for the quarter, compared to the consensus estimate of $3.83 million. During the same period in the prior year, the company earned ($1.03) EPS. Egalet Corp.’s quarterly revenue was up 259.4% on a year-over-year basis. Equities analysts anticipate that Egalet Corp. will post ($3.48) EPS for the current year.

In related news, CEO Robert S. Radie sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $5.01, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 259,900 shares of the company’s stock, valued at approximately $1,302,099. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert S. Radie sold 5,000 shares of the business’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $5.07, for a total transaction of $25,350.00. Following the sale, the chief executive officer now directly owns 259,900 shares of the company’s stock, valued at approximately $1,317,693. The disclosure for this sale can be found here. Corporate insiders own 13.20% of the company’s stock.

Large investors have recently made changes to their positions in the stock. HighTower Advisors LLC increased its stake in shares of Egalet Corp. by 8.8% in the second quarter. HighTower Advisors LLC now owns 229,664 shares of the specialty pharmaceutical company’s stock worth $1,140,000 after buying an additional 18,616 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Egalet Corp. by 139.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 240,175 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after buying an additional 140,046 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Egalet Corp. by 154.5% in the second quarter. BlackRock Fund Advisors now owns 899,471 shares of the specialty pharmaceutical company’s stock worth $4,461,000 after buying an additional 546,034 shares in the last quarter. BlackRock Investment Management LLC increased its stake in shares of Egalet Corp. by 3,736.2% in the second quarter. BlackRock Investment Management LLC now owns 84,128 shares of the specialty pharmaceutical company’s stock worth $417,000 after buying an additional 81,935 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Egalet Corp. by 12.0% in the second quarter. Vanguard Group Inc. now owns 461,128 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 49,577 shares in the last quarter. 67.18% of the stock is owned by institutional investors and hedge funds.

Egalet Corp. Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

5 Day Chart for NASDAQ:EGLT

Receive News & Ratings for Egalet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corp. and related companies with MarketBeat.com's FREE daily email newsletter.